macular telangiectasia

News

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia type 2.

News

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.